MiNK Therapeutics, Inc. (NASDAQ:INKT) Expected to Post Q1 2024 Earnings of ($0.17) Per Share

MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) – Research analysts at HC Wainwright issued their Q1 2024 earnings estimates for MiNK Therapeutics in a note issued to investors on Thursday, March 21st. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.17) per share for the quarter. HC Wainwright has a […]

Related Keywords

,Geode Capital Management ,Nasdaq ,Renaissance Technologies ,Mink Therapeutics Inc ,Blackrock Inc ,Citadel Advisors ,Free Report ,Trading Down ,Capital Management ,Get Free Report ,Mink Therapeutics ,Nasdaq Inkt ,Stinkt ,Medical ,Earnings Estimates ,Hc Wainwright ,